Immunosuppressants - Mexico

Mexico

Mexico is expected to see significant growth in the Immunosuppressants market.
In 2024, the projected revenue for this market in Mexico is estimated to reach US$241.20m.
Looking ahead, the market is anticipated to experience a compound annual growth rate (CAGR) of 15.03% from 2024 to 2029.
This positive growth trajectory is expected to result in a market volume of US$485.80m by 2029.
When compared globally, it is worth noting that United States is projected to generate the highest revenue in the Immunosuppressants market.
In 2024, the anticipated revenue from the market United States is estimated to reach a staggering US$35,470.00m.
This demonstrates the dominance of the United States in this particular market.
Mexico has seen a significant increase in the demand for immunosuppressants due to a rise in the number of organ transplant surgeries being performed in the country.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in Mexico has been increasing steadily in recent years, driven by a growing number of patients suffering from autoimmune diseases and organ transplant recipients.

Customer preferences: Mexican patients prefer to use branded immunosuppressants due to the perceived higher quality and reliability of these products. However, the high cost of branded drugs has led some patients to switch to generic alternatives, which are typically much cheaper.

Trends in the market: The market for immunosuppressants in Mexico is expected to continue growing in the coming years, driven by an aging population and an increasing prevalence of autoimmune diseases. In addition, the Mexican government has been increasing its investment in healthcare, which is expected to further boost demand for immunosuppressants.

Local special circumstances: One of the main challenges in the Mexican market for immunosuppressants is the lack of access to healthcare in certain regions of the country. This has led to a significant disparity in healthcare outcomes between different regions and socioeconomic groups.

Underlying macroeconomic factors: The Mexican economy has been growing steadily in recent years, driven by a strong manufacturing sector and increasing trade with the United States. This has led to an increase in disposable income and healthcare spending, which is expected to continue driving demand for immunosuppressants in the coming years. However, the ongoing COVID-19 pandemic has had a significant impact on the Mexican economy, which could potentially slow down growth in the healthcare sector.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.